[Antiaggregation activity of arachidonic acid conjugates with neurotropic peptides proglyprol and semax].
Bezuglov. V V VV; Gretskaia. N M NM; Vasil'eva. T M TM; Petrukhina. G N GN; Andreeva. L A LA; Miasoedov. N F NF; Makarov. V A VA
Key Findings
- Arachidonoyl‑semax reduced platelet aggregation induced by ADP, epinephrine, and arachidonic acid in vitro
- The anti‑aggregant effect increased with higher concentrations (0.018‑1.8 mM)
- Arachidonoyl‑semax was more effective than the similar arachidonoyl‑proglyprol compound
Practical Outcomes
- The finding hints that modified semax might have cardiovascular benefits, but because it’s only been shown in a lab setting at high doses, it isn’t ready for any self‑experiment or dosing protocol. More animal and human studies are needed before it could be considered for anti‑clotting or longevity use.
Summary
Researchers attached a fatty acid (arachidonic acid) to the brain‑active peptide semax and found that, in a test tube, this new compound can modestly stop platelets from clumping together, which could be good for heart health, but the effect was seen only at relatively high concentrations and only in vitro.
Abstract
The influence two original derivatives of a therapeutically important peptide, bearing arachidonic acid residue with semax and proglyprol, upon platelet aggregation have been studied in vitro. It is established that both derivatives, in contrast to the parent peptide, possess moderate anti-aggregant properties and produce a dose-dependent decrease in the interplatelet interaction induced by ADP, epinephrine, and arachidonic acid within the concentration range of 0.018 - 1.8 mM. This activity was more pronounced for arachidonoylsemax in comparison with arachidonoylproglyprol.
Study Information
pubmed
2014